A phase II, multicenter, randomized, double-blind, parallel group study to determine the optimal dose of HL301 after 7 days oral administration in acute bronchitis or acute exacerbations of chronic bronchitis patients.

Trial Profile

A phase II, multicenter, randomized, double-blind, parallel group study to determine the optimal dose of HL301 after 7 days oral administration in acute bronchitis or acute exacerbations of chronic bronchitis patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs HL 301 (Primary)
  • Indications Acute bronchitis; Acute exacerbations of chronic bronchitis
  • Focus Therapeutic Use
  • Sponsors Hanlim Pharmaceutical
  • Most Recent Events

    • 01 May 2017 Primary endpoint (Bronchitis Severity Score) has been met as per results published in the Current Medical Research and Opinion
    • 01 May 2017 Results published in the Current Medical Research and Opinion
    • 10 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top